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Intravenous IgG (ivIg) is a therapeutic alternative for lupus
erythematosus. Relative oligoclonality of circulating T-cells
in SLE has been reported. Also CD4+Foxp3+ regulatory
T-cells (Tregs) have a characteristically reduced activity in
SLE, reflected by CD25 surface density. Aiming to study
the role of Tregs for ivIg therapy, we characterized Tregs
and determined TCR spectratypes of four Vb families with
reported oligoclonality, in 15 lupus patients (14 with SLE
and one with discoid LE) treated with ivIg in cycles of 2-6
consecutive monthly infusions. Among these 15 patients,
11 responded with clinical improvement. Cell counts,
cytometry and TCR spectratypes were obtained from per-
ipheral blood at various time points before, during and
after ivIg treatment. T-cell oligoclonality was assessed as
Vb-familywise repertoire perturbation, calculated for each
patient in respect to an individual reference profile aver-
aged over all available time points. For 11/15 patients,
average Vb1/Vb2/Vb11/Vb14 repertoires were less per-
turbed under ivIg treatment than outside ivIg therapy. The
four exceptions with relatively increased average perturba-
tion during ivIg therapy included three patients who failed
to respond clinically to an ivIg therapy cycle. Patients’
Treg CD25 surface density (cytometric MFI) was, other
than Treg/CD4+ frequency, clearly reduced when com-
pared to healthy controls, but not obviously influenced by
ivIg. However, patients’ average Treg CD25 MFI was
found negatively correlated with both Vb11 and Vb14 per-
turbations measured under ivIg therapy, which indicates a
role of active Tregs in the therapeutic effect of ivIg.
Acknowledgements
This work was supported by Octapharma.
Author details
1Instituto Gulbenkian de Ciência, Oeiras, Portugal. 2IPO-CIPM/CEDOC-FCM,
Lisboa, Portugal. 3ICBAS, Porto, Portugal. 4UPMC-Paris-6/CNRS-UMR7211/AP-
HP, Paris, France. 5Hospital Sto-António, Porto, Portugal. 6Hospital Sta-Maria,
Lisboa, Portugal. 7Hospital Marmeleiros, Funchal, Portugal. 8Hospital São-
Teotónio, Viseu, Portugal. 9Hospital Garcia de Orta, Almada, Portugal.
10Hospital de Faro, Faro, Portugal.
Published: 23 November 2011
doi:10.1186/1479-5876-9-S2-P6
Cite this article as: Costa et al.: Active regulatory T-cells contribute to
broadened T-cell repertoire diversity in ivIg-treated SLE patients. Journal
of Translational Medicine 2011 9(Suppl 2):P6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1Instituto Gulbenkian de Ciência, Oeiras, Portugal
Full list of author information is available at the end of the article
Costa et al. Journal of Translational Medicine 2011, 9(Suppl 2):P6
http://www.translational-medicine.com/content/9/S2/P6
© 2011 Costa et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
